Abstract
We report an analysis of the value of a second high-dose melphalan autograft, performed at relapse, on a series of newly diagnosed myeloma patients entered into the high-dose program at our center. We conclude that relapse-free survival after the first autograft is a major prognostic factor in determining outcome.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Disease Management
-
Disease-Free Survival
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Melphalan / therapeutic use
-
Multiple Myeloma / mortality
-
Multiple Myeloma / therapy*
-
Prognosis
-
Recurrence
-
Salvage Therapy
-
Transplantation, Autologous